omniture
上海药明生物技术有限公司 Wuxi Biologics

Latest News

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also incl...

2025-10-22 08:30 910

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2025-10-10 08:30 1084

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™,to Accelerate Biologics Development with High Titer and Superior Stability

* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integratio...

2025-09-25 19:42 1536

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Resear...

2025-09-23 12:00 2872

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...

2025-09-17 12:00 1550

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span ...

2025-09-09 18:00 2361

WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi

* Committed to net-zero across the value chain by 2050 * Aligned with 1.5°C mitigation pathways,...

2025-08-28 17:00 2530

WuXi Biologics Reports Solid 2025 Interim Results

* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operation...

2025-08-19 20:35 2126

WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ pla...

2025-08-12 17:00 1825

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quali...

2025-08-11 16:30 1695

WuXi Biologics Named to A List for CDP Supplier Engagement Assessment

* Earns CDP's highest rating for supply chain engagement on climate * Adds to other CDP recognit...

2025-08-07 08:30 1741

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

* Innovative modular design will accelerate construction and manufacturing timelines, enabling ra...

2025-07-29 16:00 3285

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regi...

2025-07-16 18:00 1804

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to en...

2025-06-30 19:00 3789

Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report

* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effe...

2025-04-29 18:47 2219

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

* Firm commitment to tackling climate change in support of United Nations Sustainable Development...

2025-04-22 16:30 4051

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,...

2025-04-18 14:30 4542

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2025-04-14 21:07 2541

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted...

2025-03-25 18:30 2688

WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year

* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development ...

2025-03-21 08:30 1860